Gland Pharma's Q4 FY 2025-26 Quarterly Results

Result Summary

• Gland Pharma Ltd reported a 5.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 26.2%.
• Its expenses for the quarter were down by 1.7% QoQ and up 14.2% YoY.
• The net profit increased 40.2% QoQ and increased 96.6% YoY.
• The earnings per share (EPS) of Gland Pharma Ltd stood at 22.23 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Gland Pharma Ltd is a pharmaceutical company that operates primarily in the development, manufacturing, and marketing of complex injectables. It serves a broad range of therapeutic areas including anti-infectives, oncology, and cardiology, among others. The company is known for its capabilities in sterile injectables, oncology, and other specialty segments. Gland Pharma maintains a significant presence in both domestic and international markets, leveraging its manufacturing capabilities to supply products across the globe. As of the latest updates available until October 2023, no specific recent major developments are noted, though the company may have ongoing projects or expansions typical to its industry.

Revenue

In Q4FY26, Gland Pharma Ltd reported a total income of ₹1854.26 crores, reflecting a 5.4% increase quarter-over-quarter (QoQ) from ₹1758.54 crores in Q3FY26 and a 26.2% increase year-over-year (YoY) from ₹1468.94 crores in Q4FY25. This growth in revenue highlights an upward trend in the company's ability to generate income over the periods in question. The consistent increase in total income, both QoQ and YoY, suggests the company is effectively expanding its revenue base, possibly through enhanced sales volumes or successful market penetration in its respective segments.

Profitability

Profitability metrics for Gland Pharma Ltd show significant growth. The Profit Before Tax (PBT) for Q4FY26 was ₹505.80 crores, marking a 39.7% increase QoQ from ₹362.13 crores in Q3FY26 and a 75.4% YoY increase from ₹288.33 crores in Q4FY25. After accounting for taxes, the Profit After Tax (PAT) stood at ₹366.68 crores for Q4FY26, which is a 40.2% increase QoQ from ₹261.48 crores in Q3FY26 and a 96.6% increase YoY from ₹186.54 crores in Q4FY25. The company’s Earnings Per Share (EPS) also rose to ₹22.23, up 40.1% QoQ from ₹15.87 and 96.4% YoY from ₹11.32, indicating a robust enhancement in shareholder value over these periods.

Operating Metrics

Total expenses for Gland Pharma in Q4FY26 were ₹1348.46 crores, showing a slight decrease of 1.7% QoQ from ₹1372.06 crores in Q3FY26 and a 14.2% YoY increase from ₹1180.60 crores in Q4FY25. This reduction in expenses QoQ, amidst growing revenue, may reflect operational efficiencies or cost management strategies. The tax expense for the quarter was ₹139.12 crores, which increased by 38.2% QoQ and 36.7% YoY, aligning with the rise in PBT. No specific financial ratios like P/E ratio or debt-to-equity ratio can be calculated from the provided data, as additional information such as market capitalization or balance sheet figures are required. The overall financial performance shows a healthy increase in profitability, with revenue growth outpacing expense growth, resulting in improved margins.